As of July 1, 2023, the Centers for Medicare and Medicaid Services (CMS) implemented an updated National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP) edit. The revised codes include 80305, 80306, and 80307 for presumptive drug tests, and codes G0480-G0483 and G0659 for definitive drug tests.
ABS to showcase mSPEC™ and its integrated LC-MS/MS product and service offerings, how they can help labs reduce costs, improve efficiency, and increase uptime.
ABS Highlights Commitment to Transparency, Quality, and Safety in Cannabis Industry at Premier Medical Cannabis Conference in Marco Island, Florida
Our goal is to help customers use a product more effectively, assist with industry compliance, as well as quickly troubleshoot, diagnose, and resolve problems. Our factory-trained and certified engineers are known throughout the industry for keeping instruments operating at peak performance. To the best of my knowledge, we are the only company that provides a lab in crisis with a telephone response within 30 minutes and can have a team on-site within 48 hours when needed.
"While most issues with potency and safety measurements in the cannabis industry stem from a lack of standardized methods, there have also been reports of bad behavior. Numerous laboratories across the country have been suspended or fined for manipulating THC potency results, having deficient procedures for detecting contaminants like mold or faking those contaminant tests altogether.”
“There is no question – done right, cannabis analytical labs can generate positive cash flow quicky and offer a high return to investors,” said Joseph Coffey, chief executive officer of AltBio. “We’re definitely seeing an increase in inquiries for independent cannabis labs as more states decriminalize marijuana for medical and recreational use.”
Alternative Biomedical Solutions, the nation’s leading provider of technical expertise and services to clinical and diagnostic labs, today announced Defendable™, a new proficiency testing tool intended to help ensure drug court lab equipment is properly calibrated and working correctly.
Alternative Biomedical Solutions (ABS) announced today that Elizabeth Bell has been appointed to the position of LCMS BDE. Ms. Bell will be focused on the cannabis segment as well as supporting ABS’ full-line BDEs for confirmation testing opportunities.
Alternative Biomedical Solutions (ABS) announced today that Adrian Whipple has been appointed to the position of Chief Financial Officer. Mr. Whipple will be responsible for accounting, financial planning and analysis, treasury, tax, business operations and M&A analysis.
Alternative Biomedical Solutions (ABS) announced today that Adrian Whipple has been appointed to the position of Chief Financial Officer. Mr. Whipple will be responsible for accounting, financial planning and analysis, treasury, tax, business operations and M&A analysis.
We are bullish on our outlook for the Core Segments for the year ahead and much of it is due to the groundwork that Chris has put in place. It’s been great to have him on our team.
Partnership compliments each company’s strengths and segment expertise to service key markets in Toxicology and Cannabis segments